key: cord-1018922-rrvj5sc1 authors: Değerli, Ezgi; Derin, Sümeyra; Oruç, Kerem; Şengül Samancı, Nilay; Bedir, Şahin; Çelik, Emir; Şentürk Öztaş, Nihan; Alkan, Gülin; Demirelli, Fuat H.; Demirci, Nebi S. title: The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID‐19 patients with malignancy: A single‐center experience date: 2021-06-12 journal: J Med Virol DOI: 10.1002/jmv.27123 sha: 21accd25bccb726e9454b3965050f567665c4809 doc_id: 1018922 cord_uid: rrvj5sc1 Undoubtedly, cancer patients have suffered the most from the COVID‐19 pandemic process. However, cancer is a heterogeneous disease, and each patient has responded differently to COVID‐19. We aimed to describe the clinical characteristics and outcomes of patients with cancer and COVID‐19. We retrospectively reviewed 45 cancer patients hospitalized in the Cerrahpaşa Medical Faculty COVID‐19 department from March 23 to October 23, 2020. We analyzed the demographic characteristics, symptoms, laboratory findings, treatment, prognosis, and cancer subtypes of patients and mortality who were hospitalized for COVID‐19. Between March 23 and October 23, 2020, 45 hospitalized cancer patients who had laboratory‐confirmed COVID‐19 infection were included, with a median age of 60 years (range: 23–92). Patients were divided into two groups a survivor and a non‐survivor. Symptoms, demographic information, comorbidities, treatments for COVID‐19, and laboratory findings of the two groups were evaluated separately. Two parameters were found, which showed a significant difference between non‐survivors and survivors displaying a disadvantage for COPD and low platelet count (p = 0.044–0.038). The mortality rate of all patients was 66%. The presence of comorbidities such as COPD and low platelet count in cancer patients with COVID‐19 infection may draw the attention of physicians. of death. 3 However, cancer consists of a heterogeneous group with many subtypes and stages. Therefore, the cancer subtype and stage are essential determinants of COVID-19 prognosis. 4 There was no doubt that terminal cancer patients would suffer the most significant damage from the pandemic process. We collected and analyzed data from patients with cancer and COVID-19 hospitalized at Cerrahpaşa Medical Faculty in Istanbul, Turkey. We aimed to describe the clinical features and outcomes of patients with cancer diagnosed with COVID-19 and hospitalized and identified the risk factors associated with in-hospital mortality. The patients included were followed up in our medical oncology department. Patients were included in the study regardless of the hospital stay. Cancer patients diagnosed with COVID-19 but not hospitalized were not included in the study. Patients who could not be found to be RT-PCR positive and who could not be reached in the medical oncology follow-up file were omitted ( Figure 1 ). There was no sample size determination, and all patients meeting the inclusion criteria were recruited. The cut-off date for our study was November 1, 2020. Ethics approval was obtained from Istanbul University Cerrahpaşa-Cerrahpaşa Medical Faculty, Turkey, at the beginning of the study. We also received an approval letter from the Ministry of Health of Turkey. We obtained information about demographic data, clinical manifestations, cancer subtypes, laboratory findings, chest computed tomography (CT) examinations, treatment, and outcomes of all enrolled patients from the hospital database. The Kaplan-Meier log-rank test was used for survival analysis. Results were evaluated within a 95% confidence interval and at a significance level of p < 0.05. Fifty-two patients with active cancer hospitalized in the Cerrahpaşa Medical Faculty COVID-19 departments with documented SARS-CoV-2 infection were registered in the hospital database from March 11, 2020. Seven patients were excluded from the study because their documentation on cancer treatments was missing. The median age of the remaining 45 patients was 60 years. Twenty-three (51%) of 45 patients were men, and the median age was 66 years. Twenty-two (49%) of 45 patients were women, and the median age was 54 years. There was no difference in survival between men and women The most frequent cancer subtype was lung cancer (n = 12, 26%). According to cancer subtypes, the distribution of patients is shown in Table 1 . Twenty-two patients (48%) were receiving treatment actively for the last 4 weeks when COVID-19 was diagnosed. One of them was receiving immunotherapy (nivolumab), and one was receiving tyrosine kinase inhibitor (sunitinib), and the remaining 20 patients had received cytotoxic chemotherapy in the last 4 weeks. Although 15 patients had an active cytotoxic treatment plan, their chemotherapy was interrupted in the last 4 weeks, and they could not receive it. The remaining eight (28%) patients were not receiving oncological treatment, and two (4%) of them were being followed up without treatment because they had stage 2 disease. Six (13%) of them were terminal cancer patients and were receiving palliative care. Fatigue and dyspnea were the most common symptoms, followed by fever and cough. More than half of the patients had comorbidities, including chronic obstructive pulmonary disease, diabetes, hypertension, coronary heart disease, and asthma ( Table 2) . No significant differences in all comorbidities except COPD were observed between survivors and non-survivors. The mortality rate was significantly higher in hospitalized cancer patients with COPD (p = 0.044). Laboratory findings of all patients at the first diagnosis are given in Table 3 . Radiological findings are thorax CT at the time of initial diagnosis. Thoracic CT of 12 (27%) patients was not compatible with COVID-19. A total of 33 (73%) patients with available radiological data showed unilateral/bilateral inflammatory infiltration or groundglass opacities. There was no significant difference in radiological findings between survivors and non-survivors. Compared with survivors and non-survivors, no significant differences were detected in all laboratory results except thrombocytopenia. We found a significantly lower platelet count between non-survivors and survivors, displaying a disadvantage for COPD and low platelet count Of the 45 patients included, n = 30 (63%) received hydroxychloroquine, n = 25 (53%) received azithromycin, n = 26 (58%) received oseltamivir, n = 33 (73%) received favipiravir, and n = 5 (11%) patients received tocilizumab. Corticosteroids were given to 25 (53%) patients. Therapeutic plasma exchange treatment was not used for any patients. Noninvasive mechanical ventilation was applied to n = 5 (11%), and invasive ventilation was applied to n = 23 (51%) of 45 patients. Compared with survivors and non-survivors, it was observed that the treatments were not significantly different from the two groups. The median length of stay in the hospitalization days for the 45 patients was 14 (minimum 1 day, maximum 76 days). Intensive care unit was necessary for 26 (58%) patients and the median length of stay in the intensive care unit was 11 days (minimum 1 daymaximum 70 days). This condition could be because of evaluating elderly patients mostly (median age 60 years). Regarding underlying diseases, 67% of patients in our study had at least one comorbid disease. We found that COPD was associated with a higher risk of mortality. The mortality rate in patients diagnosed with COPD was 87%. The mortality rate in patients diagnosed with COPD was statistically significant compared to survived and non-survived (p = 0.044). The majority of patients have presented with fever and cough in many studies on COVID-19 but different from our study, dyspnea and fatigue were the most common clinical manifestations among patients with COVID-19. 9 We found unilateral or unifocal/bilateral lung lesions in 73% of patients with available records. This rate was higher than that of the general population. In the study of Wu et al., 10 bilateral lung involvement in the general population was 59%, unifocal involvement was 7% and multifocal lung involvement was 69%. In this data set, the proportion of cancer patients was only 2%. 10 There is no difference in survival between men and women in our study, but Yang et al. 11 found men were at a higher risk of mortality than women among COVID-19 patients. Many studies are showing that mortality is higher in male patients. In our study, there was no statistically significant difference in survival between men and women (p = 0.67). However, when the survival rates of stage 4 patients were examined, it was seen that this rate was higher in male patients. Ten of the stage 4 cancer patients survived and 7 (70%) of them were men. Although the stage 4 cancer rate in males is 83%, it has not created a disadvantage for survival when compared to women. In our study, 22 patients (48%) were receiving active treatment when COVID-19 was diagnosed. Moreover, almost all of them were on cytotoxic chemotherapy and had been treated in the last 4 weeks. We found that cytotoxic chemotherapy within 4 weeks before symptom onset was associated with an increased risk of mortality. The mortality rate was 90% in the group that received cytotoxic chemotherapy in the last 4 weeks and 40% in the group that did not. immunotherapy and tyrosine kinase inhibitor before the onset of COVID-19, we could not analyze the effect of immunotherapy and tyrosine kinase inhibitor on patient outcomes. There was no significant difference in the laboratory findings except for thrombocytopenia. Platelet count was significantly lower in the group that could not survive compared to survivors (p = 0.038). Platelets are critical immune cells, which play an essential role in hemostasis, coagulation, inflammatory response, and tumor biology. 13, 14 Talla et al. showed that severe infections and immunerelated factors cause secondary thrombocytopenia characterized by rapid platelet decline. 14 There are two hypotheses regarding thrombocytopenia in patients with COVID-19: The first is that coronaviruses were directly leading to hematopoietic inhibition. 15 The second is that the lung may be one of the organs in which mature megakaryocytes release platelets. Thrombocytopenia may be associated with lung damage in COVID-19 patients. 16 WHO. Rolling Updates on Coronavirus Disease (COVID-19 Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Do patients with cancer have a poorer prognosis of COVID-19? An experience in Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak COVID-19 management in a cancer center: the ICU storm Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 Pneumonia in Wuhan, China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid Platelets in inflammation and infection Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia Inactivation of three emerging viruses severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus -in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light Analysis of the level of selected parameters of inflammation, circulating immune complexes, and related indicators (neutrophil/lymphocyte, platelet/lymphocyte, CRP/CIC) in patients with obstructive diseases Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19 Efficacy of tocilizumab in patients hospitalized with Covid-19 COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study